HRTX - Heron Therapeutics: Opioid-Free Surgical Pain Relief Maven With Low Cash Reserves
2024-06-27 17:42:31 ET
Summary
- Heron Therapeutics, Inc. stock has seen a 170% gain since the last cautionary article in July 2023.
- Heron's future depends on the success of unproven new products rather than on its traditional lineup.
- Near-term financing with likely dilution is in the cards.
This is my third Heron Therapeutics, Inc. (NASDAQ: HRTX ) article, coming after July 2023's "Heron Therapeutics: Look For Continued Limbo Stick Dancing - Extreme Investor Caution Merited ("Caution Merited")." Embarrassingly, I note that Heron was trading at $1.20 when "Caution Merited" was published. Those who threw caution to the wind and bought Heron then and held have enjoyed a ~170% gain....
Heron Therapeutics: Opioid-Free Surgical Pain Relief Maven With Low Cash Reserves